← Back to Home

Mobilizing Immune Cells Against Colorectal Cancer: FDA Clears B7-H3- and IL-8-Directed CAR T Trial

A cell therapy combining tumor recognition with interference in growth signals has been cleared to move into human testing. The study will enroll patients who have exhausted standard treatments, first assessing safety and anticancer activity; estimates of its launch date still differ.

By SURL BioNews

When standard treatments fail one after another, patients with advanced colorectal cancer need more treatment avenues to explore. On September 10, the University of Colorado Anschutz Medical Campus (CU Anschutz) announced that the Food and Drug Administration (FDA) had allowed its team to begin a trial of engineered immune cells, seeking to bring CAR T-cell therapy into this difficult-to-treat setting. This clearance allows the research to move into human testing; the therapy’s safety and benefits have yet to be established.

Led by oncologist Christopher Lieu, the trial plans to enroll adults with advanced colorectal cancer who have exhausted standard treatment options, as well as children with solid tumors. CAR T therapy involves collecting patients’ T cells, genetically modifying them to recognize cancer cells, expanding them in the laboratory, and then infusing them back into the body. The initial study will assess whether these cells are safe and whether they can exert anticancer effects in humans.

CAR T therapy has achieved results in some leukemias and lymphomas, but solid tumors have proved harder to overcome. One hurdle is finding a recognition target that is abundant on cancer cells but less common in normal tissues. This study selected B7-H3; the university said this protein is present in many colorectal tumors and may therefore provide a broader means of recognition, although its actual range of applicability still needs to be confirmed through clinical research.

The team also incorporated IL-8 into the design. This signaling protein is associated with tumor growth, inflammation, and cancer spread. Researchers hope that combining the two pathways will improve the engineered cells’ chances of overcoming solid tumors’ defenses. However, existing reports do not fully explain how the cells handle IL-8 or provide sufficient animal study data for assessment; whether this dual-directed approach can produce more durable responses remains a research hypothesis awaiting validation.

Moving this design from the laboratory to patients also depends on cell manufacturing capabilities. A follow-up report from the university on September 21 stated that the experimental cells would be manufactured at its Gates Biomanufacturing Facility, with philanthropic donations helping to support the trial. A patient featured in that report was participating in a separate CAR T trial targeting GCC; that patient’s treatment experience cannot be treated as human evidence for this B7-H3 and IL-8 therapy.

The two sources still differ on when the trial will open. The university’s reports on September 10 and 21 both projected a December 2026 launch; the Colorectal Cancer Alliance wrote on September 22 that the trial was expected to open in January or February 2027. These are all planned dates and cannot establish that the trial has already begun recruiting or administering treatment.

The key question ahead is whether human research can establish acceptable safety and reveal clear signs of anticancer activity. These reports have not released human response rates, survival outcomes, or adverse reaction data for the new therapy. FDA clearance brings an experimental concept into clinical research, but whether it can become a new option after standard treatments fail still depends on the evidence accumulated through patients’ participation in the study.

References

  1. PR Newswire
  2. University of Colorado Anschutz
  3. Colorectal Cancer Alliance
  4. University of Colorado Anschutz